Article

Mitomycin solution recalled

Mobius Therapeutics LLC is conducting a recall of two lots of mitomycin for solution 0.2 mg/vial (Mitosol Kit for Ophthalmic Use) because the affected lots may be non-sterile.

 

St. Louis, MO-Mobius Therapeutics LLC is conducting a recall of two lots of mitomycin for solution 0.2 mg/vial (Mitosol Kit for Ophthalmic Use). The company is taking this voluntary action because it cannot exclude the possibility that the affected lots may be non-sterile.

These two lots may contain a strain of yeast on one or more parts in the kit and should be considered non-sterile and unsafe for use. The affected lots are Mitosol Kit for Ophthalmic Use, NDC# 49771-002-01, Expiration date 08/2013, Lot numbers M098260 and M086920.

Mobius has initiated an investigation to determine the root cause and corrective and preventative actions.

Questions may be directed to Mobius by dialing 1-877/EYE-MITO (1/877-393-6486) and pressing option “2” Monday to Friday, 8:00 a.m. to 5:00 p.m. CST. Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA’s MedWatch Adverse Event Reporting program either online, by regular mail, or by fax.

 

For more articles in this issue of Ophthalmology Times eReport, click here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
Alex Hacopian, MD, discusses a presbyopia-correcting IOL at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Parag Majmudar, MD, on bridging the gap between residency and real-world practice
Brett Bielory, MD, discusses his poster at the ASCRS annual meeting, which focuses on an under-diagnosed corneal pathology: neurotrophic keratitis.
© 2025 MJH Life Sciences

All rights reserved.